NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Tabletop particle accelerator could transform medicine and materials science 
Tokyo Medical and Dental University and the National Center of Neurology and Psychiatry are planning to develop tailored drugs for patients with genetic disorders to find treatment for extremely rare diseases.
The two Japanese medical institutions will search for rare diseases that have the potential to be treated by nucleic acid drugs from a database of around 2,250 patients.
Nucleic acid drugs are an emerging class of therapeutics,
The development will be carried out based on technology that targets the expression of disease-causing proteins in the mutant gene.
Due to the price and challenges with financial viability, pharmaceutical companies are hesitant to develop medications for exceedingly rare disorders.
According to Takanori Yokota, a professor of neurology and neurological science at Tokyo Medical and Dental University, they hope to make effective patient-tailored nucleic acid drugs and find as many people who can be treated.
The Initiative on Rare and Undiagnosed Diseases, a study that examines the DNA of people whose diseases cannot be detected or for which there is no known cure, will be used to pick participants from among the patients registered in it.
The project catalogs approximately 1,700 linked gene sequences and covers a wide spectrum of illnesses, such as neurological, cardiac, and metabolic problems.
In Japan, only one or two family lines are affected by about 70% of the diseases, and many do not have any reliable treatments.
In addition to the causative gene, factors such as age, the severity of symptoms, and the speed at which the disease is progressing will be taken into account when choosing candidate patients.
